Document:

Exhibit 10.4

 

AMENDMENT ONE

 

This AMENDMENT ONE (this “Amendment”)
dated February 22, 2022 (the “Effective Date”) to the Collaborative Agreement dated December 29, 2015 (as amended previously
and hereby, the “Agreement”) by and between BioLite, Inc., a company incorporated under the laws of Taiwan and having
its principal place of business at 3rd Floor, 248, Nei-Hu Road, Sec. 1, Taipei, 11493 Taiwan (“BioLite”) and ABVC BioPharma,
Inc. (f/k/a American BriVision Corporation), a Delaware corporation having its principle place of business at 44370 Old Warm Springs Blvd.,
Fremont, CA 94538 (“ABVC”). BioLite and ABVC are thereafter referred to as the “Parties”.
Capitalized words not otherwise defined herein shall have the meaning set forth in the Agreement.

 

WHEREAS, the Parties
desire to amend the Agreement;

NOW, THEREFORE, the Parties,
in consideration of the mutual promises herein contained and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, hereby agree to amend the Agreement as follows:

 

1.              
 Amendments to the Agreement. The Agreement is hereby amended to allow ABVC to pay any or all fees due under the Agreement
via the consolidation or forgiveness of debt owed by BioLite to ABVC. Accordingly, ABVC may now make any payments due under the Agreement
in cash, in shares of ABVC stock with equivalent value or via the cancellation of certain debts BioLite owes to ABVC, in equivalent value.
For the avoidance of doubt, payments under the Agreement include, but may not be limited to Milestone Payments due under Section 3 of
the Agreement and Royalty Charges due under Section 4 of the Agreement.

 

2.              
 Effectiveness of Agreement. Except as expressly amended by this Amendment, the provisions of the Agreement shall remain in
full force and effect.

3.              
Counterparts. This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall
be deemed an original, but all of which counterparts together shall constitute but one and the same instrument. This Amendment shall become
effective on the Effective Date. Delivery of an executed counterpart of a signature page to this Agreement, any amendments, waivers, consents
or supplements, by facsimile or other electronic transmission (including a .pdf copy sent by e-mail) shall be deemed to constitute an
original and fully effective signature of such party.

 

    

     

    

 

IN WITNESS WHEREOF the Parties hereto have caused this Amendment
to be executed, in duplicate, each Party taking a copy, as of the date first written above.

 

 

 

 

	BIOLITE, INC.	ABVC BIOPHARMA, INC.
	 	 
	By:/s/ Tsung-Shann Jiang	By:/s/ Howard Doong                  
	Name: Tsung-Shann Jiang	Name: Howard Doong
	Title: Chairman & CEO	Title: CEO
	Date: 2/22/2022	Date: 2/22/2022Document

PRIVATE AND CONFIDENTIAL

    Steven B. Hess

Dear Steven,

Re: Offer of Employment

We at MedAvail Technologies (US), Inc. (“MedAvail” or the “Company”) believe that we are able to provide you with exciting and challenging career opportunities as part of our team.

MedAvail is pleased to extend to you an offer of employment on the terms and conditions outlined below.

1.Title. You will be employed as Executive Vice President / General Manager, SpotRx. You will be reporting   directly to the Chief Executive Officer of MedAvail.  

2.Commencement Date. Your employment with us will begin on or about February 21, 2022 (your actual commencement date, the “Commencement Date”).

3.Duties and Position. You agree to devote your whole working time to the performance of your duties and to perform your duties and responsibilities, as assigned to you from time  to time by the Company, faithfully and to the best of your ability. Your duties are subject to change to meet Company needs. You agree to act in the best interests of the Company at all times. While you are employed, you agree that you will not be employed by or obtain an ownership interest in any other entity or person who is a competitor of the Company, or where you may be placed in a position of conflict with the Company. 

4.Base Salary. You will be paid an annual base salary of $335,000.00 USD (gross) subject to required statutory and other deductions which are hereby authorized by you. Your salary will be paid on a bi-weekly basis. With your authorization, this payment will be made directly into a bank account designated by you.

5.Unlimited PTO.  You will be entitled to receive unlimited Paid Time Off (PTO). Therefore, your ability to take paid time off is not a form of additional wages for services performed, but part of the Company’s promise to provide a flexible work schedule—including employees’ ability to decide when and how much time to take off. As there is no accrual of PTO, no amounts will be paid upon termination of your employment with the Company relating to unused PTO.

6.Benefits. You will be eligible to participate in our group health benefit plans the first day of the month immediately following the first day of employment. In accordance with their terms, the details of which will be available upon the commencement of your employment with the Company. The group benefit plans may be amended at the Company’s sole discretion from time to time, and so long as the modified terms apply generally to employees, you agree that any such modification will not constitute constructive dismissal.

7.Short Term Incentive Plan. The Company’s Short Term Incentive Plan (“STIP”) is a discretionary bonus plan designed to support the overall compensation structure as a component of total compensation. The Board of Directors of MedAvail Holdings, Inc. (the “Board”) or its Compensation Committee will ultimately determine the terms of the 
4890-0745-3965.1 - 2/8/2022 3:56:08 PM

STIP.  Under the current STIP terms, you will be eligible for an annual target bonus equal to fifty (50) percent of your base salary with the ability to earn up to one hundred (100) percent of your base salary based on outsized performance. The Board or its Compensation Committee  will determine the corporate objectives and approve your departmental and individual objectives for each calendar year. In general, fifty (50) percent of any STIP award is based on the achievement of the Company’s corporate objectives and the remaining fifty (50) percent is based on achievement of individual objectives to be established by the Board or its Compensation Committee after discussion with you. The  amount of any STIP bonus is determined at the discretion of the Board or its Compensation Committee and is not guaranteed to be paid in any given calendar year, or at all. The Board or its Compensation Committee will have sole discretion in determining whether any STIP award will be provided by way of cash or equity award granted pursuant to the MedAvail Holdings’ equity compensation plan as in effect from time to time. You must be an active employee working at MedAvail on the date STIP bonuses are paid and not have given notice of resignation for a future date, in order for you to be eligible for any such STIP that you would otherwise may become entitled to receive.

8.Equity Awards. Promptly following the Commencement Date, the Company will recommend to the Board that you be provided with initial equity awards covering 262,000 shares of common stock of MedAvail Holdings, Inc. (“Shares”). The initial equity awards will be divided such that 131,000 Shares will be subject to an option to purchase (the “Option”) and 131,000 shares will be subject to a restricted stock unit award that would be settled in Shares (“RSU Award”). The Option will have an exercise price per Share equal to the closing price of one Share on the date of grant.  The Option and the RSU Award  will be issued pursuant to the MedAvail Holdings, Inc. 2020 Equity Incentive Plan (the “Plan”) and will be subject to the approval of the Board or its Compensation Committee. Subject to the Stock Option Agreement, Restricted Stock Unit Award Agreement and the detailed provisions of the Plan, your Option will vest over four (4) years from the vesting commencement date, with twenty five (25) percent of the Shares subject to the Option cliff vesting on the first anniversary of the vesting commencement date and the remaining Shares vesting at the rate of 1/48th per month thereafter, and      your RSU Award will vest over three (3) years with a cliff vest every twelve (12) months following the vesting commencement date (provided that we expect the RSU Award vesting dates to occur during open trading windows when the Shares are not subject to insider trading restrictions).   Vesting is subject to you continuing to be a Service Provider (as defined in the Plan) through each vesting date. You will be required to sign both the definitive Stock Option Agreement  and Restricted Stock Unit Award Agreement documenting your Option and RSU Award in which you affirm that your rights with respect to both will be subject to the applicable terms in the Plan and your agreements. The Board or its Compensation Committee may from time to time alter the terms and conditions of the Plan on a go forward basis, without notice  to you.

9.Severance. You will be eligible to enter into a Change in Control and Severance Agreement (the “Severance Agreement”) applicable to you based on your position with the Company. The Severance Agreement will specify the severance payments and benefits you would be eligible to receive in connection with certain terminations of your employment with the Company. These protections will supersede all other severance payments and benefits you would become eligible for in the future, under any plan, program or policy that the Company may have in effect from time to time.

10.Expenses. You shall be entitled to be reimbursed for all reasonable expenses duly and properly incurred for the performance of your duties in accordance with Company policies in effect from time to time.

4890-0745-3965.1 - 2/8/2022 3:56:08 PM

11.Hours of Work. In the execution of your duties, you will be expected to work not less than forty (40) hours   per week, and in the evenings and on weekends where required. Your position is classified as exempt and does not qualify for overtime pay. You will be expected to travel  throughout the US and to the Canadian headquarters of the Company from time to time.

12.Policies. You agree to abide by the rules, regulations, personnel practices, directives, programs and policies (the “Policies”) of the Company as issued and in effect at any time during your employment. On an annual basis, or otherwise as may be reasonably required by the Company, you shall be required to certify your commitment to comply with the Policies, which are subject to amendment by the Company at any time and from time to time.

13.Conditions. This offer and your continued employment is conditional upon the following:

(a)You shall provide documentation permitted on the Form I-9 establishing that you are legally authorized to work in the United States, and you agree to indemnify the Company and its subsidiaries from any claims, damages, costs or expenses caused by the breach of this representation

(b)You shall provide a copy of a valid US passport;

(c)You shall submit to a credit check and/or security search and/or reference check to be conducted at the Company’s expense. Your employment with the Company is conditional upon the Company being satisfied with the results of such searches, in its sole discretion;

(d)You shall submit (at the request of the Company) to a drug screen at the expense of and at a laboratory designated by the Company. This offer of employment is contingent upon the Company being satisfied with the results of your drug screen, in the Company’s sole discretion; and

(e)You confirm that you have no obligations to third parties that would prevent you from performing your duties and responsibilities set out herein.

14.Confidentiality. As a condition of your continued employment, you are also required to sign and comply with an At Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement in the Company’s standard form (the “Confidentiality Agreement”) which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non- disclosure of Company proprietary information. In the event of any dispute or claim relating to or arising out of our employment relationship, you and the Company agree that
(i) any and all disputes between you and the Company shall be fully and finally resolved by binding arbitration, (ii) you are waiving any and all rights to a jury trial but all court remedies will be available in arbitration, (iii) all disputes shall be resolved by a neutral arbitrator who shall issue a written opinion, (iv) the arbitration shall provide for adequate discovery, and (v) the Company shall pay all the arbitration fees, except an amount equal to the filing fees you would have paid had you filed a complaint in a court of law. Please note that we must receive your signed Confidentiality Agreement before the Transition Date.

15.Termination of Employment. If you choose to accept this offer of employment, your employment with the Company will be at-will, which means that either you or the Company may terminate your employment at any time and for any reason with or without notice. This offer letter does not constitute a contract or guarantee of continued employment, and the Company retains the right to modify, amend, or cancel the benefits and payments summarized in this letter at any time and without prior notice.
4890-0745-3965.1 - 2/8/2022 3:56:08 PM

Upon termination of employment, by the next regularly scheduled payday you will be paid your wages earned through your date of termination as well as payment for all accrued but unused vacation days.

You acknowledge that, if you decide to terminate your employment with the Company, you will give the Company a minimum of two (2) weeks’ notice and during that period of notice, cooperate fully in the transitioning of your role.

16.Independent Legal Advice. You acknowledge that you have read and understood this Agreement and have been advised by us to seek independent legal advice and have been given a reasonable opportunity to seek and obtain such advice before signing the agreement.

17.Severability. If any provision contained in this Agreement (or part thereof) is determined to be unenforceable in whole or in part by a Court of competent jurisdiction, such invalid provision (or part thereof) shall be severed and the remaining terms will remain in full force and effect.

18.Entire Agreement. This Agreement constitutes the entire agreement between you and the Company. Any representations, oral or written, that are not expressly included in this Agreement are superseded and of no force or effect.

19.Counterparts. This Agreement may be executed simultaneously in counterparts (including by means of electronically transmitted reproductions of signature pages), each of which shall be deemed an original, but both of which together constitute one and the same instrument.

20.Governing Law. The law of the state of Illinois governs the interpretation of this Agreement without regard to any choice of law or conflict of laws rules, provisions or principles (whether of the State of Illinois or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Illinois.
We look forward to you joining MedAvail. If you choose to voluntarily accept this offer, please return an executed copy of this letter to us.
Yours truly,

MedAvail Technologies (US) Inc.

By: /s/ Mark Doerr
Title: Chief Executive Officer

4890-0745-3965.1 - 2/8/2022 3:56:08 PM

ACCEPTANCE

I have had the opportunity to review this offer of employment, understand its terms, and accept the terms offered above. I confirm that there are no terms which have been promised to me other than those described above. I acknowledge that I am able to consult with legal counsel, at my own cost, and that I am voluntarily accepting this offer.

/s/ Steven B. Hess
Steven B. Hess

						
		Date: February 11, 2022

4890-0745-3965.1 - 2/8/2022 3:56:08 PM

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]